Screener
Ionis Pharmaceuticals IONS Total Liabilities
Total Liabilities at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:Liabilities.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Liability related to sale of future royalties, net | 562,574 | 551,353 |
| Long-term lease liabilities | 262,476 | 262,383 |
| Long-term obligations | 28,435 | 28,118 |
| Total liabilities | 2,554,764 | 3,034,747 |
| Stockholders’ equity: | ||
| Common stock, $0.001 par value; 300,000,000 shares authorized, 165,636,792 and 163,304,875 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively | 166 | 163 |
| Additional paid-in capital | 3,311,837 | 3,145,402 |
| Accumulated other comprehensive loss | (33,897) | (25,281) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's total liabilities?
- Ionis Pharmaceuticals (IONS) reported total liabilities of $2.55B in Q2 2026.
- How has Ionis Pharmaceuticals's total liabilities changed year-over-year?
- Ionis Pharmaceuticals's total liabilities increased by 8.6% year-over-year, from $2.35B to $2.55B.
- What is the long-term trend for Ionis Pharmaceuticals's total liabilities?
- Over 5 years (2020 to 2025), Ionis Pharmaceuticals's total liabilities has grown at a 14.4% compound annual growth rate (CAGR), from $1.55B to $3.03B.
- What does total liabilities mean?
- The sum of all current and non-current obligations — everything the company owes to creditors, employees, governments, and other stakeholders.
Ask your AI about Ionis Pharmaceuticals's total liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude